Finn
REGN Biotechnology · Large cap · Biotech · Profitable pharma · Thesis updated November 1, 2026

Dupixent surges while EYLEA HD defends the eye franchise

01 Running thesis

A stronger core, a thinner pipeline

Regeneron is firing on its main cylinders. Dupixent, sold with Sanofi, reached $6.5 billion in global Q3 2026 net sales and grew 35 percent on a constant currency basis. The company also fully repaid its Sanofi development balance earlier in the year, which allowed it to record a full share of collaboration profits for the first time this quarter.

The United States eye franchise is successfully transitioning. EYLEA HD generated $700 million in Q3 2026, growing 62 percent from a year ago. This newer drug now accounts for nearly two thirds of the United States retinal franchise, helping the company hold its ground even as older EYLEA sales fall against heavy competition.

However, challenges remain. The FDA delayed its decision on a pre-filled syringe for EYLEA HD to the end of 2026, which keeps a key defense tool out of doctors' hands. Multiple new 2-mg biosimilars are expected to launch in late 2026, which will test how well the combined eye franchise can maintain growth.

Following a melanoma trial failure earlier in the year, the clinical pipeline has fewer near-term catalysts. The stock story relies on Dupixent growing even larger, EYLEA HD fending off new rivals, and upcoming data for drugs like cemdisiran proving the pipeline can still deliver.

Oct 2026▲Q3 results showed strong momentum with Dupixent reaching $6.5 billion globally and EYLEA HD hitting $700 million in the United States. The company also began recording its full share of Sanofi profits.
Jul 2026▲EYLEA HD U.S. sales surpassed legacy EYLEA for the first time, proving the franchise transition is working. The company also fully repaid its Sanofi development balance, boosting future profit margins.
Jul 2026▼The FDA delayed its expected Q2 decision for the EYLEA HD pre-filled syringe. Management now hopes for a resolution by the end of 2026.
May 2026▼Regeneron said fianlimab plus Libtayo failed to meet the primary endpoint in a Phase 3 first-line metastatic melanoma study. This removed a major near-term cancer catalyst and made the pipeline question more important.
Apr 2026→Q1 results showed the same split story. Dupixent grew 31 percent on a constant currency basis, while legacy EYLEA U.S. sales fell 36 percent and the combined U.S. EYLEA franchise declined year over year.
Apr 2026▼The 10-Q confirmed U.S. EYLEA pressure from competition and biosimilars. It also disclosed a temporary Limerick manufacturing interruption that hurt gross margin, though supply was not expected to be affected.
Feb 2026▼The 2025 10-K moved EYLEA biosimilar competition from a future risk to a current headwind. It also kept the EYLEA HD pre-filled syringe decision in focus for Q2 2026.
Oct 2025▼The FDA issued a complete response letter for the EYLEA HD pre-filled syringe tied to Catalent inspection findings. This delayed a useful product enhancement for defending the eye franchise.
02 Business model

Science, sales, and partners

Regeneron is a fully integrated biotech company. That means it discovers drugs, tests them, makes them, and sells some of them itself. Its research engine uses antibody discovery tools to create new drug candidates.

Money comes from two main places. First, Regeneron records direct product sales in the United States for drugs like EYLEA, EYLEA HD, Libtayo, and Praluent. In Q3 2026, combined United States sales for the EYLEA franchise were $1.1 billion.

Second, Regeneron earns collaboration revenue from partners. Sanofi is the most important partner because it records Dupixent sales globally and shares profits with Regeneron. Bayer records EYLEA sales outside the United States and shares profits.

This model works when the science keeps producing big products and partners sell them well. It breaks when a key drug faces biosimilars, when a trial fails, or when a contract manufacturer delays an important product form.

03 Product portfolio

The drugs that matter

Growth engine

Dupixent

Dupixent treats allergic and inflammatory diseases. Sanofi records sales, while Regeneron earns its share of the profits.

Cash cow

EYLEA HD and EYLEA

These eye drugs treat diseases such as wet age-related macular degeneration. EYLEA HD is now the larger seller in the United States, replacing the declining legacy product.

Growth engine

Libtayo

Libtayo is a cancer drug used in non-small cell lung cancer and other settings. Regeneron records global net product sales, which reached $550 million in Q3 2026.

Steady

Praluent

Praluent lowers LDL cholesterol. Regeneron handles the United States market, while Sanofi handles sales outside the United States and pays Regeneron royalties.

Option

Cemdisiran

This is a pipeline asset targeting myasthenia gravis. The company expects an FDA decision on its application in November 2026.

04 Business segments

Revenue split, not operating segments

Sanofi collaboration revenue47%growing fast
Net product sales40%modest
Bayer collaboration revenue8%declining
Other revenue and other collaboration5%modest

Regeneron reports one operating segment. The mix below reflects recent historical revenue trends, showing where money comes from rather than separate business units.

05 Risk factors

What could go wrong

Dupixent concentration

High impact · Medium odds

The bull case leans heavily on Dupixent. It is growing quickly, but any slowdown would be felt across the whole company. Regeneron's Sanofi collaboration revenue is its largest growth engine.

We watchGlobal Dupixent sales growth and Regeneron's Sanofi collaboration profit share each quarter.

EYLEA biosimilar wave

High impact · High odds

Multiple 2-mg biosimilars are expected to launch in the second half of 2026. Legacy EYLEA is falling rapidly, and these new rivals will test whether EYLEA HD can defend the total franchise.

We watchCombined United States EYLEA HD and EYLEA sales in late 2026.

Pre-filled syringe delay

Medium impact · Medium odds

The FDA delayed its decision on the EYLEA HD pre-filled syringe past the originally expected date. The company now hopes for approval by year end 2026. A pre-filled syringe is needed to make the drug easier for doctors to use.

We watchFDA decision by year end 2026.

Pipeline gap

High impact · Medium odds

The melanoma study failure earlier this year removed a major near-term catalyst. The company needs other pipeline drugs to prove they can become the next major growth driver.

We watchFDA decisions and clinical readouts for cemdisiran and garetosmab.
06 Quick answers

In one breath

Why is Dupixent so important to Regeneron?

Dupixent is Regeneron's main growth driver through its Sanofi partnership. In Q3 2026, global Dupixent net sales reached $6.5 billion and grew 35 percent.

What is happening to EYLEA?

EYLEA HD is growing rapidly and replacing the older version. In Q3 2026, EYLEA HD United States sales were $700 million, while legacy EYLEA continued to decline under competitive pressure.

What is the Sanofi collaboration?

Regeneron partners with Sanofi to sell drugs like Dupixent globally. They split the profits, and recently expanded the alliance to share profits equally on four next-generation antibodies.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 1, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Regeneron Q3 2026 earnings call transcript
  2. Regeneron Q2 2026 Form 10-Q
08 Explore the industry

Comparable Biotechnology companies

Companies near Regeneron Pharmaceuticals, Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today